A team of Indian scientists has
identified new genes and new biological pathways that are specific to driving
oral cancer associated predominantly with smokeless tobacco consumption in
India. Further detailed study on these discoveries may lead to finding better
therapies for oral cancer, the researchers point out. The findings have been
published on Monday in the journal Nature Communications.The Indian group is
part of the International Cancer Genome Consortium (ICGC), an initiative
started in 2009, to understand the genomic basis of 50 different types of
cancer with clinical and societal importance around the globe.The Indian
component is being conducted collaboratively by the National Institute of
Biomedical Genomics (NIBMG), Kalyani, West Bengal, and the Tata Memorial Centre
(TMC), Mumbai. This is the first set of results to come out of the India
Project, which has been noted as an important contribution to cancer genomics.Oral
cancer is the eighth most common cancer worldwide and is the leading cancer
among males in India. Unlike in the West, where 65 per cent of oral cancers are
tongue cancer, in India, oral cancer predominantly (60 per cent) is of the
lining of the mouth, lower gum and other mucosal regions of the oral cavity,
termed the Oral Squamous Cell Carcinoma of the gingivo-buccal region (OSCC-GB).
Tobacco chewing is a major cause of OSCC-GB, which accounts for over half of
the oral cancers in India.
Cancer is known to be associated
with changes in the DNA contained in the cells of the tumour tissues. However,
these genetic changes — triggered by lifestyle or other environmental factors
such as exposure to tobacco, chemicals and radiation — occur only in
non-reproductive cells and are called somatic alterations. But, as Dr. Partha
Majumder of the NIBMG, who led the research, explains, most somatic alterations
do not cause the abnormal growth, which results in cancer. Gene alterations
that do provide this growth advantage to cancerous cells over normal cells are
called driver mutations. Though past studies have identified several genes
associated with oral cancer, these have not been systematically catalogued.
More pertinently, as the paper says, “Oral cavity comprises sub-sites with
distinct biological features. It is therefore likely that genes driving cancers
in these sub-sites may be different.”The study included 110 subjects suffering
from OSCC-GB, about half of who were between the age of 40 and 50, and nearly
all were tobacco users. Eighty-eight per cent of the patients were male and 94
per cent were in advanced stages of cancer. Fifty patients, who had not
undergone any treatment, were identified for investigation into the genetics of
OSCC-GB and the data on the remaining 60 were used to test the validity of the
discoveries.
Using the technique of
massively-parallel DNA sequencing, blood and tumour DNA of each patient were
screened for all genes — about 20,000 — in the human genome. On an average, 85
somatic alterations were found on each patient. But, as mentioned above, only
some of these are potential drivers.The study found 10 significantly mutated
genes that were associated with OSCC-GB. These are TP53, FAT1, CASP8, NOTCH1,
HRAS, USP9X, MLL4, UNC13C, ARID2 and TRPM3. Of these, the first five have been
implicated earlier in the cancer called, the Head and Neck Squamous Cell
Carcinoma (HNSCC), of which OSCC-GB is a subtype. The remaining five are new,
which seem to be specific to OSCC-GB. These new genes were found to be altered
in 10-22 per cent of the patients.Any alteration in a ‘tumour suppressor gene’
means that it cannot perform its normal function of tumour suppression, which
can lead to cancer. Sixty-two per cent of patients exhibited mutations in TP53,
a very important tumour suppresser gene. In fact, four of the five genes
identified earlier are tumour suppresser genes, according to Dr. Majumder.While
MLL4 acts in concert with TP53, and increases its expression, both MLL4 and
ARID2 are involved in regulating key biological processes in the cell, such as
programmed cell death, inefficiency of which can cause cancer. The authors note
that TRPM3 may also be indirectly involved in tumour suppression. “Overall,”
says the paper, “tumour suppresser genes, compared with oncogenes [cancer
causing genes], are predominantly involved in oral cancer; this fact may have
therapeutic implications.”
The remaining two new genes —
UNC13C and TRPM3 — are involved in biochemical pathways associated with
neurotransmitter release and, according to the authors, alterations in these
could be related to predisposition to tobacco addiction, which enhances the
risk of oral cancer.“The characterisation of a large sample of the OSCC-GB
subtype provides a unique contribution to the literature on characterisation of
HNSCCs,” Dr. Carolyn Hutter of the National Human Genome Research Institute
(NHGRI), USA, observed in an e-mail message.
No comments:
Post a Comment